ProQR Therapeutics N.V. Statistics
Share Statistics
ProQR Therapeutics N.V. has 103.20M shares outstanding. The number of shares has increased by 27.7% in one year.
| Shares Outstanding | 103.20M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 26.35% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 74.28M |
| Failed to Deliver (FTD) Shares | 150 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 364.70K, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 364.70K |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.49% |
| Short Ratio (days to cover) | 0.71 |
Valuation Ratios
The PE ratio is -5.16 and the forward PE ratio is -8.47.
| PE Ratio | -5.16 |
| Forward PE | -8.47 |
| PS Ratio | 22.28 |
| Forward PS | 23 |
| PB Ratio | 3.51 |
| P/FCF Ratio | 7.19 |
| PEG Ratio | n/a |
Enterprise Valuation
ProQR Therapeutics N.V. has an Enterprise Value (EV) of 45.84M.
| EV / Earnings | -1.63 |
| EV / Sales | 7.04 |
| EV / EBITDA | -1.9 |
| EV / EBIT | -1.44 |
| EV / FCF | 2.27 |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.1.
| Current Ratio | 3.54 |
| Quick Ratio | 3.54 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.4 |
| Cash Flow / Debt | 5.02 |
| Interest Coverage | -26.48 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -51.98%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.2% |
| Return on Capital (ROIC) | -51.98% |
| Revenue Per Employee | 41.76K |
| Profits Per Employee | -180.25K |
| Employee Count | 156 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -78.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 35.96% in the last 52 weeks. The beta is 0.25, so ProQR Therapeutics N.V.'s price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | 35.96% |
| 50-Day Moving Average | 3.35 |
| 200-Day Moving Average | 2.34 |
| Relative Strength Index (RSI) | 42.77 |
| Average Volume (20 Days) | 1.58M |
Income Statement
In the last 12 months, ProQR Therapeutics N.V. had revenue of 6.51M and earned -28.12M in profits. Earnings per share was -0.35.
| Revenue | 6.51M |
| Gross Profit | 6.38M |
| Operating Income | -31.86M |
| Net Income | -28.12M |
| EBITDA | -24.10M |
| EBIT | -31.86M |
| Earnings Per Share (EPS) | -0.35 |
Balance Sheet
The company has 118.92M in cash and 19.73M in debt, giving a net cash position of 99.19M.
| Cash & Cash Equivalents | 118.92M |
| Total Debt | 19.73M |
| Net Cash | 99.19M |
| Retained Earnings | -400.85M |
| Total Assets | 106.85M |
| Working Capital | 52.77M |
Cash Flow
In the last 12 months, operating cash flow was 21.55M and capital expenditures -1.37M, giving a free cash flow of 20.18M.
| Operating Cash Flow | 21.55M |
| Capital Expenditures | -1.37M |
| Free Cash Flow | 20.18M |
| FCF Per Share | 0.25 |
Margins
Gross margin is 9.79K%, with operating and profit margins of -48.91K% and -43.17K%.
| Gross Margin | 9.79K% |
| Operating Margin | -48.91K% |
| Pretax Margin | -42.70K% |
| Profit Margin | -43.17K% |
| EBITDA Margin | -369.93% |
| EBIT Margin | -489.09% |
| FCF Margin | 309.75% |
Dividends & Yields
PRQR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -12.68% |
| FCF Yield | 7.08% |
Analyst Forecast
The average price target for PRQR is $8, which is 189.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 189.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -3.61 |
| Piotroski F-Score | 2 |